Immunotherapy after Chemo-Radiation shows promise for lung cancer
NCT ID NCT07161388
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether the immunotherapy drug durvalumab can help people with limited-stage small-cell lung cancer when given after chemoradiation. Researchers will track 200 patients in China to see how long the cancer stays under control and how safe the treatment is. The goal is to understand real-world effectiveness outside of a controlled trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (an immunotherapy drug)
What this could lead to
If successful, this could show that durvalumab helps delay cancer progression after standard chemoradiation for limited-stage small-cell lung cancer.
What could go wrong
This is an observational study, not a randomized trial, so results may be less definitive. Side effects of immunotherapy can include inflammation of organs, and the study is still recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIMITED STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBeijing, China
-
Research Site
RECRUITINGCangzhou, China
-
Research Site
RECRUITINGDongguan, China
-
Research Site
RECRUITINGFuzhou, China
-
Research Site
RECRUITINGGuangzhou, China
-
Research Site
RECRUITINGHuzhou, China
-
Research Site
RECRUITINGJinan, 250117, China
-
Research Site
RECRUITINGJinan, China
-
Research Site
RECRUITINGNanjing, China
-
Research Site
RECRUITINGNanning, China
-
Research Site
RECRUITINGNingbo, China
-
Research Site
RECRUITINGShanghai, China
-
Research Site
RECRUITINGShenyang, China
-
Research Site
RECRUITINGShijiazhuang, China
-
Research Site
RECRUITINGTaiyuan, China
-
Research Site
RECRUITINGTianjing, China
-
Research Site
TERMINATEDTianjing, China
-
Research Site
RECRUITINGWuhan, China
-
Research Site
RECRUITINGWuxi, China
-
Research Site
RECRUITINGYangzhou, China
-
Research Site
RECRUITINGZhengzhou, China